Paul Chapman Appointed Chief Executive Officer
Lexington, MA – Quanterix Corporation, developer of the Single Molecule Array (Simoa) technology, announced today that it has appointed Paul Chapman as its new President and Chief Executive Officer. Mr. Chapman joins the company at a pivotal time, as it moves from development to commercialization of its revolutionary digital ELISA platform that improves conventional immunoassay sensitivity 1000-fold.
“Quanterix’s Simoa technology has the potential to dramatically change the world of biomarker research and clinical diagnostics,” says Chapman. “I am very excited to work with the exceptional team at Quanterix to make that potential a reality in the near future.”
Prior to joining Quanterix, Mr. Chapman was Vice President of the BioPharm Process Solutions business at EMD Millipore where he was responsible for the Marketing and R&D teams in the $800 million business. Prior to joining Millipore, he was the Vice President, Hospital Solutions for Roche Near Patient Testing in Austria, where he held P&L responsibility for Roche’s decentralized Cardiac, Blood Gas / Electrolyte and Hospital Glucose businesses. Mr. Chapman was also the International Business Development Manager at Roche Molecular Diagnostics for blood screening and, prior to that, held an array of sales and marketing positions at Roche Diagnostics Canada (where he began his career in 1993) focused primarily in the Molecular Diagnostics field. Mr Chapman has a B.Sc. in Microbiology from the University of Western Ontario, a B.Sc (hons) in Immunology from the University of Guelph Ontario, and graduated from the Marketing Management Program (MMP) from the Richard Ivy School of Business.
“Paul is a visionary leader with a strong track record in several businesses and I have great confidence that he will make Quanterix a huge success”, says Martin Madaus, Executive Chairman of the Board of Directors. “His background and capabilities to bring new technologies to market successfully make him uniquely qualified for Quanterix.”
Dr. Martin Madaus, who was previously CEO and Executive Chairman of the Board of Directors, will continue at Quanterix as the Executive Chairman, while Mr. Chapman takes the reins of the company’s operations as President and Chief Executive Officer to prepare the organization for the launch of its first product in 2013.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts.
Media contact for Quanterix:
Share this page